Product Information
KEPPRA XR 750 MG TABLET is a brand product labeled by UCB, Inc., priced at $13.4813 per EA under NDC 50474059966. Its NADAC has been published 668 times since Nov 28, 2013.
FDA first approved this application on Sep 12, 2008. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the levetiracetam market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
750 mg/1
Manufacturer
UCB, Inc.NDC
50474059966
Classification
Brand
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LEVETIRACETAMApproval Type
New Drug (NDA)
FDA Application
NDA022285FDA Approved
9/12/2008
TE Code
AB
On Market Since
4/1/2009
Pharmacological Classes
Price Statistics
The NADAC for KEPPRA XR 750 MG TABLET has been published 668 times since Nov 28, 2013, and over the history we have for it it has risen 78.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $13.4813 per EA |
|---|---|
| All-time high | $13.5325 (Jun 10, 2026) |
| All-time low | $7.5372 (Nov 28, 2013) |
| 52-week high | $13.5325 |
| 52-week low | $13.1740 |
| Median price | $10.5642 |
| Average price | $10.8250 |
| Largest weekly change | +9.9% (Jan 14, 2015) |
| Weeks tracked | 668 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 99% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
UCB, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
levetiracetam market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of KEPPRA XR 750 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for KEPPRA XR 750 MG TABLET, manufactured by UCB, Inc., is $13.4813 per EA (NDC 50474059966), effective Sep 30, 2026.
How has the price of KEPPRA XR 750 MG TABLET changed over time?
Over the history we have for it, the NADAC for KEPPRA XR 750 MG TABLET has risen 78.9%. It has been tracked across 668 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for KEPPRA XR 750 MG TABLET?
Since Nov 28, 2013, the NADAC for KEPPRA XR 750 MG TABLET has ranged from a low of $7.5372 (Nov 28, 2013) to a high of $13.5325 (Jun 10, 2026), with a median of $10.5642 per EA.
Are there cheaper alternatives to KEPPRA XR 750 MG TABLET?
Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, LEVETIRACETAM 750 MG TABLET, is $0.1092 per EA — about 99% below KEPPRA XR 750 MG TABLET.
Who manufactures KEPPRA XR 750 MG TABLET?
KEPPRA XR 750 MG TABLET (NDC 50474059966) is labeled by UCB, Inc., and CMS classifies it as a brand product.